You are here

Novel QcrB Inhibitors for the Treatment of Tuberculosis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI145514-01A1
Agency Tracking Number: R41AI145514
Amount: $225,343.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA18-575
Timeline
Solicitation Year: 2018
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-06-01
Award End Date (Contract End Date): 2021-02-28
Small Business Information
4255 CABIN CT
New Palestine, IN 46163-9485
United States
DUNS: 081244749
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 PHILIP HIPSKIND
 (317) 690-4885
 pahipskind@lgenia.com
Business Contact
 PHILIP HIPSKIND
Phone: (317) 690-4885
Email: pahipskind@lgenia.com
Research Institution
 SEATTLE CHILDREN'S HOSPITAL
 
4800 SAND POINT WAY NE
SEATTLE, WA 98105-3901
United States

 Domestic nonprofit research organization
Abstract

Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among
infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial
Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds,
will die due to AMR associated with TB. Long treatment times and increasing resistance to TB
drugs have created the need to find new compounds with shorter treatment times and novel
mechanisms of action. Triazolopyrimidine (TZP) compounds may lead to treatment shortening
because they are effective against both replicating and non-replicating Mtb, and may address
drug resistance because they target QcrB (ubiquinone cytochrome C oxidoreductase), a protein
not currently targeted with existing TB drugs. During Phase I, we propose to optimize the
physicochemical and ADME-PK properties of the TZP series and study the effects of this series
in combination with other respiratory inhibitors such as bedaquiline. We will identify compounds
with suitable potency, in vivo exposure, and tolerability. We will use an optimized compound to
demonstrate efficacy in an animal model of TB infection and we will determine the kill kinetics and
growth inhibition properties of the compounds alone and in combination with other respiratory
inhibitors under replicating and non-replicating conditions.
At the conclusion of these studies, we will have demonstrated feasibility that the TZP series, in
combination with other respiratory inhibitors, results in treatment shortening. We will have
completed a proof of concept animal study to demonstrate in vivo efficacy. During Phase II, we
will complete lead optimization, further characterize the biological activity, and expand in vivo
studies.Project Narrative
Tuberculosis (TB) infection results in more deaths than HIV and is the leading infectious disease killer
responsible for more than 1 million deaths each year. Treatment requires at least 6 months of therapy and drug
resistance is increasingly common, which necessitates the development of agents that kill faster through novel
targets. We will develop a triazolopyrimidine compound as a new TB therapy, which may lead to treatment
shortening by acting on both replicating and non-replicating bacteria, and has a novel mode of action, which
addresses drug resistance.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government